Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 28;9(8):e70230.
doi: 10.1002/jgh3.70230. eCollection 2025 Aug.

Self-Injection Satisfaction and Safety of CT-P17 (Yuflyma), a High-Concentration Adalimumab Biosimilar, in Patients With Crohn's Disease: A Cross-Sectional Study

Fei Yang Pan  1 , Thanaboon Chaemsupaphan  2   3 , Sacha Cartwright  1 , Rupert Leong  1   2
Affiliations

Self-Injection Satisfaction and Safety of CT-P17 (Yuflyma), a High-Concentration Adalimumab Biosimilar, in Patients With Crohn's Disease: A Cross-Sectional Study

Fei Yang Pan et al. JGH Open. .

Abstract

Background: CT-P17 (Yuflyma), a biosimilar to adalimumab (Humira), offers a cost-effective alternative with improved access for individuals with immune-mediated inflammatory diseases (IMIDs). Assessing patient experience with autoinjector usability and comfort is crucial for ensuring adherence and satisfaction. This study is the first to evaluate patient-reported satisfaction and safety of CT-P17 specifically in people with Crohn's disease (CD).

Aims: To evaluate patient satisfaction and safety of CT-P17 in CD.

Methods: This cross-sectional study included 15 adults (median age 39.9 years) with CD from two Australian hospitals. All participants had prior experience with biologic therapy and used an autoinjector. Patients had either transitioned from adalimumab to CT-P17 or had been receiving CT-P17 for at least 4 weeks. Data collected included baseline demographics, the Harvey Bradshaw Index (HBI), and the Self-Injection Assessment Questionnaire (SIAQ), a validated instrument assessing patient experience, confidence, and satisfaction with self-injection. SIAQ domain scores ranged from 0 (worst) to 10 (best), with higher scores indicating more positive self-injection experiences.

Results: SIAQ scores indicated positive patient experiences. Mean (SD) scores showed high comfort (8.33 ± 1.67), strong self-confidence (8.38 ± 1.53), positive self-image (9.00 ± 2.64), minimal pain/skin reactions (9.22 ± 0.93), and ease of use (8.80 ± 1.89). Overall satisfaction was high (8.76 ± 1.38). HBI scores remained low (mean 0.7), indicating stable disease control.

Conclusions: CT-P17 is well-tolerated in CD patients, with high satisfaction and minimal injection discomfort. Its ergonomic autoinjector design supports ease of use. While larger studies are needed, these findings support the broader adoption of adalimumab biosimilars to enhance patient autonomy and reduce healthcare costs.

Keywords: Crohn's disease; adalimumab; biosimilar; inflammatory bowel disease; patient satisfaction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Zhao M., Gönczi L., Lakatos P. L., and Burisch J., “The Burden of Inflammatory Bowel Disease in Europe in 2020,” Journal of Crohn's & Colitis 15, no. 9 (2021): 1573–1587, 10.1093/ecco-jcc/jjab029. - DOI - PubMed
    1. Feuerstein J. D., Ho E. Y., Shmidt E., et al., “AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease,” Gastroenterology 160, no. 7 (2021): 2496–2508, 10.1053/j.gastro.2021.04.022. - DOI - PMC - PubMed
    1. D'Amico F., Peyrin‐Biroulet L., and Danese S., “Benefits of Biosimilars in the Management of Patients With Inflammatory Bowel Disease: An International Survey,” Journal of Clinical Medicine 13, no. 11 (2024): 3069, 10.3390/jcm13113069. - DOI - PMC - PubMed
    1. Torres J., Bonovas S., Doherty G., et al., “ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment,” Journal of Crohn's and Colitis 14, no. 1 (2020): 4–22, https://academic.oup.com/ecco‐jcc/article/14/1/4/5620479. - PubMed
    1. Raine T., Bonovas S., Burisch J., et al., “ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment,” Journal of Crohn's & Colitis 16 (2022): 2–17, 10.1093/ecco-jcc/jjab178. - DOI - PubMed

LinkOut - more resources